Market revenue in 2020 | USD 848.4 million |
Market revenue in 2028 | USD 2,516.4 million |
Growth rate | 14.6% (CAGR from 2020 to 2028) |
Largest segment | Lymphoma |
Fastest growing segment | Lymphoma |
Historical data covered | 2018 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 46.88% in 2020. Horizon Databook has segmented the North America hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
North America dominated the hemato-oncology testing market in 2020 and is expected to maintain its position during the forecast period. Increasing awareness about cancer, high disposable income, favorable reimbursement policies, and well-established healthcare infrastructure are some of the key factors boosting the regional market.
The U.S. accounted for the largest share in North America. Key factors contributing to its dominance include local presence of major market players, easy availability of advanced solutions, higher diagnosis & treatment rate of blood cancers, introduction of technologically advanced solutions, and increasing incidence of leukemia & lymphoma.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America hemato oncology testing market , including forecasts for subscribers. This continent databook contains high-level insights into North America hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account